bims-myxlip Biomed News
on Myxoid liposarcoma
Issue of 2023–08–13
two papers selected by
Laura Mannarino, Humanitas Research
  1. Myxoid Liposarcoma of the Breast Mimicking Phyllodes Tumor: A Case Report.
  2. New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting.
  1. J Korean Soc Radiol. 2023 Jul;84(4): 952-957
    Myxoid Liposarcoma of the Breast Mimicking Phyllodes Tumor: A Case Report.
    Se Jin Lee, Jung Kyu Ryu, Kyu Yeoun Won, Sang-Ah Han.
      Myxoid liposarcoma is an extremely rare malignant breast tumor. We report the case of a 44-year-old woman who had myxoid liposarcoma of the breast with a history of phyllodes tumor and describe the imaging findings on US, mammography, and MRI. Before surgery, the mass was considered to be a recurrent phyllodes tumor. However, using US, we retrospectively identified some differences between myxoid liposarcomas and phyllodes tumors.
    Keywords:  Breast; Elastography; Myxoid Liposarcoma; Phyllodes Tumor
    DOI:  https://doi.org/10.3348/jksr.2022.0146
  2. J Hematol Oncol. 2023 Aug 08. 16(1): 93
    New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting.
    Matthieu Roulleaux-Dugage, Antoine Italiano.
      Immunotherapy has revolutionized cancer treatment, but currently, immuno-oncology agents have not been approved for patients with soft tissue sarcomas. However, there is growing evidence suggesting that immunotherapy could be an effective therapeutic strategy for this group of diseases. Here, we reviewed the latest advances of immunotherapy trials from the 2023 American Society of Clinical Oncology Annual Meeting, including some novel and encouraging combination regimens. Further research is still needed to fully understand the optimal use of these agents in sarcoma treatment.
    DOI:  https://doi.org/10.1186/s13045-023-01486-6
This page is being maintained by Thomas Krichel. It was last updated on 2024‒11‒22 at 4:24.